Ublituximab is the third anti-CD20 therapy for multiple sclerosis and a worthy rival to Ocrevus and Kesimpta.
Aubagio
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Kesimpta: Highly Effective New Drug for Multiple Sclerosis
Ofatumumab by Novartis is as good and convenient as Ocrevus by Roche against multiple sclerosis.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Ponvory: Another Drug for Multiple Sclerosis
Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod).